|
|
Browse products Anticancer agents in preclinical trials Anticancer molecular libraries Other drug agents
|
MedKoo product information:
RG7167
Description of RG7167: RG7167 is a potent, orally bioavailable, highly selective MEK inhibitor. It potently inhibits the MAPK signaling pathway activation and tumor cell growth. Single-agent oral administration resulted in complete tumor regression in xenograft models.
Current developer: Roche/Genentech; Chugai Pharmaceuticals Co. Ltd.
|
Contact MedKoo: Email: sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
||||||||||||||
About us | Services | Products | News | Careers | Contact us